Divozilimab not checked

Biocad · BCD-132 · Anti-CD20

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
3 active
7 in total
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Ant-CD0 human monoclonal antibody, Concentrate for solution for infusion intravenously”In the company’s words, NCT07136389 on ClinicalTrials.gov
Tested for
Systemic Scleroderma, Neuromyelitis Optica Spectrum Disorders, Systemic Lupus Erthematosus
Main trialPhase 3
“The study is a randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult patients of both sexes diagnosed with active systemic scleroderma according to the ACR/EULAR 2013 criteria with a modified Rodnan skin score (mRSS) of 10 to 20. In patients having signs of ILD, the Forced Vital Capacity (FVC) should be at least 40 % of the due value. The study will include patients of either sex aged ≥16 years with systemic scleroderma according to the ACR/EULAR 2013 criteria, with a modified…”In the company’s words, NCT05726630 on ClinicalTrials.gov
Other names
BCD-132 · Anti-CD20

Other drugs for Systemic Scleroderma

All 57 drugs for Systemic Scleroderma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 1 Oct 2024 Clinical Study of Divozilimab in Patients With Systemic Scleroderma
Phase 3Active, not recruiting Jan 2025 Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
Phase 1Recruiting 1 Jan 2026 Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus
Phase 3Completed 9 Sep 2022 An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis
Phase 3Completed 16 May 2024 An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD
Phase 2Completed 13 Jul 2020 Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
Phase 1Completed 18 Oct 2018 Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Divozilimab

Following is part of Solo: you see every change to Divozilimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in